Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 90764-84-4 | MDL No. : | MFCD18255876 |
Formula : | C8H9NO4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | OCOFPEDHFWODKY-UHFFFAOYSA-N |
M.W : | 183.16 g/mol | Pubchem ID : | 23002395 |
Synonyms : |
|
Num. heavy atoms : | 13 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.25 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 44.18 |
TPSA : | 68.65 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.71 cm/s |
Log Po/w (iLOGP) : | 1.57 |
Log Po/w (XLOGP3) : | 0.99 |
Log Po/w (WLOGP) : | 0.8 |
Log Po/w (MLOGP) : | -1.19 |
Log Po/w (SILICOS-IT) : | 0.73 |
Consensus Log Po/w : | 0.58 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -1.74 |
Solubility : | 3.31 mg/ml ; 0.0181 mol/l |
Class : | Very soluble |
Log S (Ali) : | -2.02 |
Solubility : | 1.75 mg/ml ; 0.00955 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.65 |
Solubility : | 4.06 mg/ml ; 0.0222 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.06 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75.6% | Synthesis Example 8 Synthesis of 2-[[[(4,6-Dimethoxypyridin-2-yl)carbonyl]-amino]sulfonyl]benzoic Acid Methyl Ester [Compound (I-257)] Using 2-methoxycarbonylbenzenesulfonamide [Compound (III-3)] (0.106 g, 0.49 mmol) and <strong>[90764-84-4]4,6-dimethoxypicolinic acid</strong> [Compound (II-77)] (0.09 g, 0.49 mmol), the Compound (I-257) was synthesised according to the process of Synthesis Example 3. White solid, yield: 0.14 g, percent yield: 75.6%, m.p.: 156-158 C. IR KBr cm-1: 1728, 1617, 1473, 1392, 1347, 1293, 1182. 1H-NMR (60 MHz, CDCl3, delta): 3.73 (3H, s, OCH3 or COOCH3), 3.9 (3H, s, OCH3 or COOCH3), 4.0 (3H, s, OCH3), 6.3 (1H, d, J=2 Hz, pyridine ring H), 7.2 (1H, d, J=2 Hz, pyridine ring H), 7.5-7.8 (3H, m, aromatic ring H), 8.1-8.5 (1H, m, aromatic ring H), NH indistinctness. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
70.5% | (2) Synthesis of 4,6-dimethoxypicolinic acid [Compound (II-77)] Using 4,6-dimethoxypicolinic acid methyl ester [Compound (V-77)] (0.148 g, 0.75 mmol), the Compound (II-77) was synthesised according to the process of Synthesis Example 20 (3). White solid, m.p.: 145-148 C., yield: 0.0966 g, percent yield: 70.5%. IR KBr cm-1: 1701, 1620, 1473, 1296, 1218. 1H-NMR (60 MHz, d6-DMSO, delta): 3.75 (3H, OCH3), 3.80 (3H, s, OCH3), 6.4 (1H, d, J=2 Hz, pyridine ring H), 7.1 (1H, d, J=2 Hz, pyridine ring H), COOH indistinctness. |
[ 149744-21-8 ]
6-(Benzyloxy)pyridine-2-carboxylic acid
Similarity: 0.83
[ 29681-43-4 ]
Methyl 4-methoxypyridine-2-carboxylate
Similarity: 0.81
[ 149744-21-8 ]
6-(Benzyloxy)pyridine-2-carboxylic acid
Similarity: 0.83
[ 1214334-70-9 ]
5-Bromo-6-methoxypicolinic acid
Similarity: 0.78
[ 149744-21-8 ]
6-(Benzyloxy)pyridine-2-carboxylic acid
Similarity: 0.83